Biomaterials-Based Delivery of Therapeutic Antibodies for Cancer Therapy.

Abstract

Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody-mediated cancer therapy, such as instability in vivo, poor tumor penetration, limited response rate, and undesirable off-target cytotoxicity. In recent years, an increasing number of biomaterials-based delivery systems have been reported to enhance the antitumor efficacy of antibody drugs. This review summarizes the advances and breakthroughs in integrating biomaterials with therapeutic antibodies for enhanced cancer therapy. A brief introduction to the principal mechanism of antibody-based cancer therapy is first established, and then various antibody immobilization strategies are provided. Finally, the current state-of-the-art in biomaterials-based antibody delivery systems and their applications in cancer treatment are summarized, highlighting how the delivery systems augment the therapeutic efficacy of antibody drugs. The outlook and perspective on biomaterials-based delivery of antitumor antibodies are also discussed.

• Authors: Qian-Ni Ye, Yue Wang, Song Shen, Cong-Fei Xu, Jun Wang
• Journal: Advanced healthcare materials (Adv Healthc Mater) Vol. 10 Issue 11 Pg. e2002139 (06 2021) ISSN: 2192-2659 [Electronic] Germany
• PMID: 33870637 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2021 Wiley-VCH GmbH.

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents, Immunological
• Biocompatible Materials

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Agents, Immunological
• Biocompatible Materials (therapeutic use)
• Humans
• Immunotherapy
• Neoplasms (drug therapy)